Ionis Pharmaceuticals, Inc.
CHIRALLY ENRICHED OLIGOMERIC COMPOUNDS
Last updated:
Abstract:
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having one or more chirally enriched phosphorothioate intemucleoside linkages. In certain embodiments, the modified oligonucleotide decreases expression of target mRNA.
Status:
Application
Type:
Utility
Filling date:
4 Oct 2019
Issue date:
9 Dec 2021